A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Healthy Participants

Treatments: Drug: Bisacodyl; Drug: BMS-986166

Study type: Interventional

Funder types: Industry

Identifiers

NCT05409157

IM018-010

Details and patient eligibility

About

The purpose of this study is to assess the drug levels of BMS-986166 in healthy male participants.

Enrollment: 7 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male participants as determined by no clinically significant deviation from normal in medical history, physical examination, 12-lead ECGs, or clinical laboratory determinations
• Body mass index between 18.0 to 33.0 kg/m2 (inclusive)

Exclusion criteria

• Any significant acute or chronic medical illness
• Current or recent history of constipation or irregular bowel movement (less than 1 bowel movement per day within the last 1 week)
• History of allergy (such as rash, hives, breathing difficulties) to any medications, either prescription or nonprescription

Other protocol-defined inclusion/exclusion criteria apply

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

7 participants in 1 patient group

Treatment Group 1: BMS-986166

Experimental group

Treatment:

Drug: BMS-986166

Drug: Bisacodyl